ACIU CH0329023102

Report

Delayed Nasdaq - 05/20 04:00:01 pm EDT
3.150	USD		+0.96%

05/17	AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award	AQ
05/10	AC Immune's Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Published In JAMA Neurology	AQ
05/09	AC Immune Says Anti-Abeta Vaccine Found to be Safe in Adult Patients With Down Syndrome	MT

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Nasdaq

05/17/2022	05/18/2022	05/19/2022	05/20/2022		Date
3.1(c)	3.2(c)	3.12(c)	3.15(c)	3.15	Last
58 388	168 783	354 420	101 711	101 711	Volume
+3.68%	+3.23%	-2.50%	+0.96%	+0.96%	Change

More quotes

Estimated financial data (e)

Sales 2022	2,40 M 2,47 M 2,47 M
Net income 2022	-79,6 M -82,0 M -82,0 M
Net Debt 2022	- - -
P/E ratio 2022	-3,18x
Yield 2022	-

Sales 2023	55,0 M 56,6 M 56,6 M
Net income 2023	-28,1 M -28,9 M -28,9 M
Net Debt 2023	- - -
P/E ratio 2023	-9,45x
Yield 2023	-

Capitalization	234 M 241 M 241 M
Capi. / Sales 2022	97,6x
Capi. / Sales 2023	4,26x
Nbr of Employees	-
Free-Float	44,6%

More Financials

Company

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines...

Sector

Biotechnology & Medical Research

Calendar

08/10

Earnings Release

More about the company

Ratings of AC Immune SA

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

All news about AC IMMUNE SA

05/17	AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award	AQ
05/10	AC Immune's Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Published I..	AQ
05/09	AC Immune Says Anti-Abeta Vaccine Found to be Safe in Adult Patients With Down Syndrome	MT
05/09	AC Immune's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published i..	AQ
05/09	AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Publishe..	CI
04/28	AC IMMUNE : Condensed Consolidated Balance Sheets (Unaudited) - Form 6-K	PU
04/28	AC IMMUNE : Q1 Earnings Snapshot	AQ
04/28	AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
04/28	AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update	AQ
04/27	AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conf..	AQ
04/08	AC Immune Appoints Chief Human Resource Officer, Interim CFO	MT
04/08	AC IMMUNE : Reports Changes to Senior Management - Form 6-K	PU
04/08	Joerg Hornstein to join Lundbeck as Chief Financial Officer and Head of Corporate Funct..	AQ
04/08	AC Immune SA Announces Senior Management Changes	CI
04/08	AC Immune SA Announces Executive Changes	CI

More news

News in other languages on AC IMMUNE SA

05/09	AC Immune affirme que le vaccin anti-Abeta s'est avéré sûr chez les patients adultes at..
05/09	Les résultats du vaccin anti-Abêta d'AC Immune SA issus de l'étude de phase 1b dans le ..
04/28	AC Immune SA annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/08	AC Immune nomme un directeur des ressources humaines et un directeur financier intérima..
04/08	AC Immune SA annonce des changements de direction

More news

Analyst Recommendations on AC IMMUNE SA

2021	SVB Leerink Adjusts AC Immune's Price Target to $15 from $17, Keeps Outperform Rating	MT
2021	AC IMMUNE : HC Wainwright Adjusts AC Immune's Price Target to $16 From $11, Keeps Buy Rati..	MT
2020	AC IMMUNE : Down 43%; Semorinemab Didn't Meet Endpoint in Early Alzheimer's Disease	DJ

More recommendations

Provided by Scoopnest.com

Analysis

U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients